As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
10 Analysts have issued a Aligos Therapeutics Inc forecast:
10 Analysts have issued a Aligos Therapeutics Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 3.17 3.17 |
60%
60%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -78 -78 |
16%
16%
|
EBIT (Operating Income) EBIT | -79 -79 |
16%
16%
|
Net Profit | -74 -74 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Lawrence Blatt |
Employees | 70 |
Founded | 2018 |
Website | www.aligos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.